euro adhoc: Intercell AG / Joint Ventures/Cooperation/Collaboration / Intercell enters into strategic partnership with Wyeth for the use of its IC31TM adjuvant in various selected infectious disease v

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

12.09.2006

» Worldwide agreement with Wyeth for the use of Intercell's fully
synthetic novel adjuvant IC31TM in various selected infectious
disease vaccine programs » Up to USD 77 million in upfront, option
and milestone payments as well as royalties on product net sales »
Further use of Intercell’s adjuvant IC31TM in the development of
novel vaccines with high unaddressed medical need.

Intercell AG (VSE, "ICLL") today announced that it has closed a
worldwide non-exclusive agreement under which Wyeth has the right to
use Intercell's fully synthetic novel adjuvant IC31TM in various
selected infectious disease vaccine programs. Under the agreement,
Intercell may be entitled to receive up to USD 77 million in upfront,
option and milestone payments as well as royalties on product net
sales.

"After having partnered a number of our vaccine candidates derived
from our extremely successful Antigen Identification Program® with
leading players in the vaccine industry, we are convinced that our
adjuvant IC31TM will also generate significant value in the vaccine
sector", says Alexander von Gabain, Intercell's Chief Scientific
Officer. "We are happy that we could add Wyeth, a company with a high
commitment to developing and commercializing innovative products in
the vaccine sector, to the list of our top partners."

About IC31TM

Vaccines, based on antigens alone, are not sufficient to provide full
protection. Adjuvants are needed to educate the immune system to
recognize and eliminate the pathogens efficiently.

IC31TM is an adjuvant that induces T-cell and B-cell responses by
using a unique synthetic formulation which combines the
immunostimulating properties of an anti-microbial peptide, KLK, and
an immunostimulatory oligodeoxynucleotide, ODN1a. The two component
solution can be simply mixed with antigens; no conjugation is
required.

Intercell currently uses IC31™ in collaborations with a number of
global vaccine companies and biotech companies. These collaborations
include amongst others the development of a tuberculosis vaccine in
Phase I clinical trials, which has been partnered with the Danish
Statens Serum Institut.

end of announcement euro adhoc 12.09.2006 07:10:29
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market